Navigation Links
Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Date:11/12/2007

THE WOODLANDS, Texas, Nov. 12 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions. The initial Phase 1 clinical trial of LX2931 is planned as a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers, designed to evaluate the safety, tolerability, and pharmacokinetics of LX2931. Lexicon expects to initiate clinical trials with LX2931 following FDA review.

"As an orally-delivered modulator of lymphocyte activity, we believe LX2931 has potential to be an important new therapy for rheumatoid arthritis and other autoimmune disorders," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "We can now add immunology to the list of therapeutic areas with clinical-stage compounds from Lexicon's drug discovery pipeline."

Rheumatoid arthritis is an autoimmune disorder characterized by stiffness, pain, swelling, and limitation of motion in multiple joints. More than 2 million Americans suffer from rheumatoid arthritis, which, if left untreated, can result in disfigurement and disability from irreversible joint damage. According to the National Institutes of Health (NIH), autoimmune disorders affect between 14.7 and 23.5 million people in the United States.

LX2931 was developed at Lexicon as an inhibitor of a key enzyme in the sphingolipid pathway, which controls lymphocyte circulation and trafficking to peripheral sites in the body during an inflammatory response. As with Lexicon's other clinical and preclinical programs, the LX2931 target enzyme was identified through Lexicon's gene knockout program, Genome5000(TM). Knockout mice lacking this enzyme had a significantly decreased number of circulating lymphocytes and were resistant to inflammation in a wide range of assays modeling processes involved in the development of arthritis and other autoimmune conditions. Because inappropriate activation of lymphocytes is associated with autoimmune disorders, including rheumatoid arthritis, reduction of lymphocyte buildup at sites of disease activity holds promise as a new therapeutic mechanism. Preclinical studies with LX2931 showed a robust and reproducible reduction of inflammation in animal models of arthritis. Additionally, LX2931-treated animals showed a rapid, dose-dependent reduction in peripheral lymphocyte counts.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and autoimmune diseases. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon's drug discovery system has been so productive that Lexicon plans to move ten drug candidates into human clinical trials by the end of 2010. This strategic initiative is referred to as the 10to10 program. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX2931 and the potential therapeutic and commercial potential of LX2931. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX2931 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
10. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017 - First major agreements signed ... market expected to grow by a CAGR of approximately 6-9% ... holding company which operates globally across a number of sectors, announces ... of notable successes and is well-positioned for further expansion within the ... ...
(Date:1/16/2017)... Research and Markets has announced the addition of the ... ... myeloma drugs market to grow at a CAGR of 9.19% during ... scenario and the growth prospects of the global multiple myeloma drugs ... the revenue generated from the sales of branded and generic drugs ...
(Date:1/16/2017)... -- An aneurysm develops due to the weakening of blood vessel ... occur in any artery, it happens most often in the ... legs. Most aortic aneurysms occur in the section of the ... abdominal aortic aneurysms, sometimes in the chest referred as thoracic ... abdomen is about 2 cm but in the case of ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. Steven ... Board of Trustees and as a core faculty member, teaching master’s and doctoral courses ... of psychology at Pepperdine University, where he earned his Doctor of Psychology degree in ...
(Date:1/16/2017)... Utah (PRWEB) , ... January 16, 2017 , ... With ... officially opened on January 8 for use by sports teams and the general public. ... indoor volleyball courts that can also be converted into basketball or pickleball courts. The ...
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... GA (PRWEB) , ... January 16, 2017 , ... ... to announce their recent partnership with an innovator in the wheelchair accessibility industry, ... to motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Aesthetic Surgery Journal , the official journal of The American Society for Aesthetic ... retraction surgery. The procedure is designed to correct drooping, retracted lower eyelids, which ...
Breaking Medicine News(10 mins):